<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911018-0016</DOCNO><DOCID>911018-0016.</DOCID><HL>   International Brief -- L'Oreal S.A.:   Cosmetics Firm Purchases   Pharmaceuticals Company</HL><DATE>10/18/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   F.ORE</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>COSMETICS, PERSONAL CARE, OVER-THE-COUNTER REMEDIES (COS)DRUG MANUFACTURERS (DRG)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>EUROPE (EU)FRANCE (FR)WESTERN EUROPE (WEU)</RE><LP>   L'Oreal S.A. said it reinforced its position inpharmaceuticals with the purchase of Laboratoires DelagrangeS.A.   The price of the transaction wasn't disclosed.</LP><TEXT>   Delagrange will be integrated with the French cosmeticsmaker's pharmaceutical unit, Synthelabo, which posted a 14%rise in consolidated sales last year, to 3.3 billion Frenchfrancs ($568 million). L'Oreal said the addition ofDelagrange will boost sales to about five billion francs,creating a pharmaceutical unit with a &quot;European dimension.&quot;   L'Oreal said it already has bought a 58% share inDelagrange from Sesif, the laboratory's holding company. Theremainder will be purchased as part of a capital boost at anunspecified later date.   The reconstituted pharmaceutical unit is slated to spendone billion francs on central nervous system, cardiovascularand gastro-intestinal research.   Synthelabo accounted for 11% of L'Oreal group consolidatedsales in 1990. The pharmaceutical unit is strongerdomestically than abroad, with France accounting for roughlythree-quarters of its drug sales.</TEXT></DOC>